Doxylamine/pyridoxine transdermal patch

Drug Profile

Doxylamine/pyridoxine transdermal patch

Alternative Names: AQS-1303; Pyridoxine/doxylamine transdermal patch

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aequus Pharmaceuticals
  • Class Antiemetics; Picolines; Pyridines; Sedating antihistamines; Small molecules; Vitamins
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Nausea and vomiting

Highest Development Phases

  • Clinical Phase Unknown Nausea and vomiting

Most Recent Events

  • 07 Sep 2017 Pharmacokinetics and adverse events data from a proof-of-concept trial in Nausea and vomiting released by Aequus Pharmaceuticals
  • 07 Sep 2017 Aequus Pharmaceuticals completes a proof-of-concept trial for Nausea and Vomiting in Canada
  • 29 Aug 2017 Clinical trials in Nausea and vomiting in Canada (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top